Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Biome warns of ongoing slowness in bioplastics division
(Sharecast News) - Bioplastics and radio frequency technology specialist Biome Technologies reported challenges in its bioplastics division, alongside positive developments in its Stanelco RF technologies division, in an update on Monday. The AIM-traded firm said the bioplastics division was facing production and regulatory difficulties with two key customers, leading to subdued revenues in the first quarter.
Despite initial expectations that the issues would be resolved by mid-2024, the company said it had become evident that significant revenue recovery would be delayed until later in the year as technical validations were finalised.
Additionally, the North American coffee packaging market - a crucial segment for Biome - was showing signs of reduced buoyancy compared to previous periods.
In contrast, the Stanelco RF technologies division had secured several major contracts, including a significant one in 2023 and three additional large contracts announced this year.
The contracts were expected to generate substantial revenue in 2024, supporting the division's diversification into new applications within the scientific glass industry and high-value medical markets.
Biome said the division was currently focused on designing and building these systems, with deliveries scheduled for the latter half of the year.
Given the delays in the Bioplastics division, the board said it now expected group revenues for the year ending 31 December to be significantly below market expectations.
However, the impact on revenue was anticipated to be partially offset by higher margins and lower overheads.
As a result, Biome Technologies projected a small underlying EBITDA loss for the year.
"Working capital management will be a significant focus for management in the second half of the year as the RF division completes four large system builds and the bioplastics division stocks its raw material pipelines ahead of anticipated customer ramp-ups in North America," the board explained in its statement.
"In these circumstances, the board is examining ways to ensure that the group has sufficient working capital going forward.
"As of 30 June, the group had an unaudited cash balance of £0.6m, no bank debt and convertible loan notes outstanding of £1.3m."
At 1002 BST, shares in Biome Technologies were down 42.86% at 40p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
